摘要
目的探讨阿帕替尼靶向治疗标准化疗失败的晚期胃癌患者的临床效果。方法选取2017年1月至2019年1月间西安市第一医院收治的行化疗失败的62例晚期胃癌患者,采用随机数字表法分为试验组和对照组,每组31例。对照组患者采用支持性治疗,试验组患者采用阿帕替尼靶向治疗,比较两组患者的临床疗效和对血清癌胚抗原(CEA)、糖类抗原199(CA199)水平及生存时间的影响。结果试验组患者疾病缓解率为29.0%,缓解率为64.5%,均高于对照组的6.5%和32.3%,差异均有统计学意义(均P<0.05)。治疗前,两组患者CEA和CA199水平比较,差异无统计学意义(P>0.05)。治疗后,两组患者CEA和CA199水平均降低,且试验组患者均低于对照组,差异均有统计学意义(均P<0.05)。试验组患者中位无进展生存时间和中位生存时间均高于对照组,差异均有统计学意义(均P<0.05)。试验组患者不良反应发生率为41.9%,略高于对照组的35.5%,差异无统计学意义(P>0.05)。结论阿帕替尼靶向治疗能提高标准化疗失败晚期胃癌患者的生存时间和疾病总缓解率及控制率,降低血清肿瘤标志物,不良反应发生率稍高,应注意预防。
Objective To explore the clinical efficacy of apatinib in patients with advanced gastric cancer who failed standard chemotherapy.Methods Sixty-two patients with advanced gastric cancer who failed chemotherapy at Xi’an No.1 Hospital from January 2017 to January 2019 were selected as the research subjects.They were divided into an experimental group and a control group using the random number table method with 31 patients in each group.Patients in the experimental group were given targeted therapy with apatinib and patients in the control group were given supportive treatment.Clinical efficacy and the effect on serum carcinoembryonic antigen(CEA),carbohydrate antigen 199(CA199)and survival time were compared between the two groups.Results The disease remission rate and disease control rate was29.0%and 64.5%,respectively in the experimental group and 6.5%and 32.3%,respectively in the control group(all P<0.05).The difference in the levels of CEA and CA199 were not significant between the two groups before intervention(P>0.05).After intervention,levels of CEA and CA199 decreased in both groups and the experimental group was lower than the control group(all P<0.05).Progression-free survival(PFS)and overall survival(OS)were higher in the experimental group than in the control group(all P<0.05).The incidence of adverse reactions was 41.9%in the experimental group which was slightly was higher than 35.5%of the control group(P>0.05).Conclusion Apatinib can significantly improve the survival,overall disease remission rate and control rate,and reduce the levels of serum tumor markers in the treatment of advanced gastric cancer after chemotherapy had previously failed,but the incidence of adverse reactions is slightly high which deserves additional attention.
作者
张玥
梁聪
ZHANG Yue;UANG Cong(Department of Transfusion,Xi'an No.1 Hospital,Xi'an 710002,China;Department of Respiratory and Digestive Medicine,Second People’s Hospital of Shaanxi Province,Xi’an 710000,China)
出处
《中国肿瘤临床与康复》
2020年第5期521-524,共4页
Chinese Journal of Clinical Oncology and Rehabilitation
关键词
晚期
胃肿瘤
阿帕替尼
靶向治疗
生存时间
Advanced stage
Gastric tumors
Apatini
Targeted therapy
Survival time
